SCHEMBL6769905

SCHEMBL6769905

COC(=O)C(CC1CO1)NS(=O)(=O)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 12/20 0.53
MMP9 P14780 9/20 0.53
ADAMTS4 O75173 5/20 0.53
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 2/20 0.49
CYP2C9 P11712 2/20 0.49
TSHR P16473 2/20 0.49
CYP2C19 P33261 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
MAPT P10636 1/20 0.49
MMP13 P45452 4/20 0.49
MMP8 P22894 1/20 0.49
MMP3 P08254 3/20 0.48
MMP1 P03956 2/20 0.48
MMP7 P09237 2/20 0.48
ADAMTS5 Q9UNA0 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6779702 0.91 MMP2 (0.52) MMP2MMP9SMN1; SMN2MMP13MMP8
SCHEMBL6774654 0.91 MMP2 (0.53) MMP2MMP9MMP13MMP3MMP1
SCHEMBL6768565 0.91 MMP2 (0.53) MMP2MMP9SMN1; SMN2MMP13MMP8
SCHEMBL15943338 0.79 MMP2 (0.75) MMP2MMP9ADAMTS4MAPTMMP13
SCHEMBL6772209 0.77 ADAMTS4 (0.53) MMP2MMP9ADAMTS4MMP13MMP8
SCHEMBL14191413 0.74 MMP2 (0.67) MMP2MMP9ADAMTS4MAPTMMP13
SCHEMBL1737163 0.74 POLB (0.51) MMP2MMP9ADAMTS4SMN1; SMN2MMP13
SCHEMBL10076124 0.74 POLB (0.51) MMP2MMP9ADAMTS4SMN1; SMN2MMP13
SCHEMBL1735671 0.74 POLB (0.51) MMP2MMP9ADAMTS4SMN1; SMN2MMP13
SCHEMBL12808878 0.73 MMP2 (0.76) MMP2MMP9ADAMTS4MMP13MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6762198-B2 SUCH AS 2-((4'-METHOXY-(1,1'-BIPHENYL)-4-YL)-SULFONYL)-AMINO-3-(2-PHENOXYMETHYL -(1,3)DIOXAN-2-YL)PROPIONIC ACID THE PROCTER & GAMBLE COMPANY 2004-07-13 US disclosed
US-20030225074-A1 Dihetero-substituted metalloprotease inhibitors THE PROCTER & GAMBLE COMPANY 2003-12-04 US disclosed
US-6566381-B1 For therapy of arthritis, cancer, cardiovascular disorder, skin disorder, ocular disorder, inflammation and gum disease THE PROCTER & GAMBLE COMPANY 2003-05-20 US disclosed
EP-1165530-A2 DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2002-01-02 EP disclosed
WO-2000051993-A2 DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2000-09-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225074-A1 Dihetero-substituted metalloprotease inhibitors ADAM9, ADAM17, ADAM8 MMP2 10/4885MMP9 7/4885ADAMTS4 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.